Quidel (NASDAQ:QDEL) is scheduled to be announcing its earnings results after the market closes on Wednesday, February 21st. Analysts expect the company to announce earnings of $0.20 per share for the quarter.

Quidel (QDEL) opened at $44.31 on Wednesday. The company has a current ratio of 6.28, a quick ratio of 5.68 and a debt-to-equity ratio of 0.70. The firm has a market cap of $1,510.00, a P/E ratio of -276.94, a P/E/G ratio of 1.39 and a beta of 1.02. Quidel has a 1 year low of $19.97 and a 1 year high of $49.47.

In other Quidel news, CEO Douglas C. Bryant sold 36,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $37.36, for a total value of $1,344,960.00. Following the completion of the transaction, the chief executive officer now owns 296,493 shares of the company’s stock, valued at approximately $11,076,978.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Douglas C. Bryant sold 12,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 28th. The shares were sold at an average price of $36.72, for a total transaction of $440,640.00. Following the completion of the transaction, the chief executive officer now directly owns 296,493 shares of the company’s stock, valued at approximately $10,887,222.96. The disclosure for this sale can be found here. Insiders sold a total of 370,260 shares of company stock valued at $15,293,980 in the last three months. 22.00% of the stock is currently owned by corporate insiders.

A number of equities analysts recently weighed in on QDEL shares. Canaccord Genuity reaffirmed a “buy” rating and set a $52.00 price objective (up previously from $48.00) on shares of Quidel in a research report on Thursday, December 21st. BidaskClub cut shares of Quidel from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Zacks Investment Research cut shares of Quidel from a “hold” rating to a “strong sell” rating in a research report on Thursday, December 28th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $60.00 price objective on shares of Quidel in a research report on Wednesday, January 24th. Finally, Barclays increased their price objective on shares of Quidel from $45.00 to $49.00 and gave the stock an “overweight” rating in a research report on Thursday, November 2nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $53.50.

TRADEMARK VIOLATION WARNING: “Quidel (QDEL) Scheduled to Post Earnings on Wednesday” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://theolympiareport.com/2018/02/14/quidel-qdel-scheduled-to-post-earnings-on-wednesday.html.

Quidel Company Profile

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.

Earnings History for Quidel (NASDAQ:QDEL)

Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.